Bisdas Theodosios, Zambas Neophytos, Zertalis Marios, Theodorides Panagiotis, Iatrou Nikolaos, Dimopoulos Christos, Charalambous Nikolas
Clinic of Vascular Surgery III, Athens Medical Group, Athens, Greece.
University of Nicosia Medical School, Nicosia, Cyprus.
J Endovasc Ther. 2024 Mar 25:15266028241241006. doi: 10.1177/15266028241241006.
To analyze the early performance and efficacy of the first commercially available off-the-shelf precannulated multibranched endograft in the endovascular repair of pararenal abdominal aortic aneurysms (PAAAs). The device received European marketing approval in late 2020.
Between January 2021 and June 2023, a retrospective analysis of prospectively collected data from all consecutive patients with pAAAs undergoing implantation of the E-nside precannulated inner-branched endograft was conducted in 2 centers. The primary outcome measure was technical success defined as the composite endpoint of successful (1) delivery of the 24F endograft, (2) use of the precannulation tubes, and (3) implantation of the bridging stent-grafts (BSGs) to the target vessels. Main secondary endpoints were mortality, target vessel instability (TVI), absence of type I or III endoleak, reintervention, spinal cord ischemia, and supra-celiac aortic coverage.
Twenty-one patients (20 men, mean age: 71 years) were included in this study with a mean follow-up of 14±7.7 months. Nine patients had a symptomatic aneurysm (43%). Technical success amounted to 95% (in one patient, an iliofemoral conduit was necessary to advance the device). One out of 112 BSGs (1%, right renal artery) occluded at 30 days, resulting in freedom from TVI and reintervention rate at 12 months of 95%. No type I or III endoleaks were identified during follow-up. One patient (5%) died at 13 months due to non-aneurysm-related death, and 1 patient (5%) developed spinal cord ischemia. No other major perioperative complications were observed. Mean supra-celiac aortic coverage reached 52±8%.
Given the imperative need for an off-the-shelf endograft tailored to address PAAAs, the E-nside stent-graft demonstrated encouraging outcomes in this study. Nevertheless, it is essential to emphasize that the extent of aortic coverage mandates the production of a truncated variant.
The endovascular repair of urgent pararenal aortic aneurysms remains still an unsolved problem in the endovascular era since there are no available off-the-shelf dedicated fenestrated or branched endografts. This paper confirms the safety and efficacy of the off-the-shelf precannulated inner branched endograft for this specific indication.
分析首款市售预插管多分支腔内移植物在肾旁腹主动脉瘤(PAAA)血管腔内修复中的早期性能和疗效。该装置于2020年末获得欧洲市场批准。
2021年1月至2023年6月,在2个中心对前瞻性收集的所有连续接受E-nside预插管内分支腔内移植物植入的PAAA患者数据进行回顾性分析。主要结局指标为技术成功,定义为成功实现以下复合终点:(1)输送24F腔内移植物;(2)使用预插管;(3)将桥接支架型人工血管(BSG)植入目标血管。主要次要终点包括死亡率、目标血管不稳定(TVI)、无I型或III型内漏、再次干预、脊髓缺血以及腹腔干上方主动脉覆盖情况。
本研究纳入21例患者(20例男性,平均年龄:71岁),平均随访14±7.7个月。9例患者患有有症状的动脉瘤(43%)。技术成功率达95%(1例患者需要使用髂股导管推进装置)。112个BSG中有1个(1%,右肾动脉)在30天时闭塞,12个月时TVI和再次干预率均为95%。随访期间未发现I型或III型内漏。1例患者(5%)在13个月时因非动脉瘤相关死亡,1例患者(5%)发生脊髓缺血。未观察到其他主要围手术期并发症。腹腔干上方主动脉平均覆盖范围达52±8%。
鉴于迫切需要一款现成的腔内移植物来治疗PAAA,E-nside支架型人工血管在本研究中显示出令人鼓舞的结果。然而,必须强调的是,主动脉覆盖范围要求生产一种缩短型变体。
在血管腔内治疗时代,紧急肾旁腹主动脉瘤的血管腔内修复仍是一个未解决的问题,因为尚无现成的专用开窗或分支腔内移植物。本文证实了现成的预插管内分支腔内移植物用于该特定适应症的安全性和有效性。